MorphoSys: MOR202 Shows Early Signs Of Clinical Activity - Quick Facts

(RTTNews) - MorphoSys AG (MPSYY.PK) reported first safety and efficacy data on its drug candidate MOR202 from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma. The company reported that MOR202 demonstrated promising early signs of activity, and cases of long-lasting tumor control were already observed in early cohorts.

The company said the preliminary clinical data showed that MOR202 was safe and well tolerated with a best-in-class infusion tolerability as a 2-hour infusion. Infusion reactions in patients receiving MOR202 without dexamethasone were mostly mild to moderate and mainly limited to the first infusion. In patients receiving MOR202 in combination with dexamethasone, no infusion reactions were observed.

The study is ongoing and the higher doses of MOR202 are being evaluated in combination with dexamethasone.